Related Experiment Videos
Abrogation of tumor vasculature using gene therapy
1Aventis-Gencell, Department of Antiangiogenesis, Hayward, California 94545, USA. nesbit.mark@rp-rorer.com
Abstract:
Anti-angiogenic gene therapy may be a rational approach in the treatment of solid tumors. The current state of gene therapy with regard to the abrogation of tumor vasculature is reviewed in this article and the different administration vehicles are noted. Furthermore, this article discusses the influence of vascular support cells in the tumor vasculature and choice of pre-clinical model for anti-angiogenic cancer gene therapy.
Insights
Anti-angiogenic gene therapy offers a promising strategy for treating solid tumors by targeting tumor vasculature. This review examines current gene therapy approaches, delivery vehicles, and the role of vascular support cells in preclinical models.
Area of Science:
- Oncology
- Gene Therapy
- Vascular Biology
Background:
- Solid tumors rely on angiogenesis for growth and metastasis.
- Anti-angiogenic strategies aim to inhibit tumor blood vessel formation.
- Gene therapy presents a novel approach to deliver anti-angiogenic agents.
Purpose of the Study:
- To review the current status of gene therapy for abrogating tumor vasculature.
- To discuss various administration vehicles used in anti-angiogenic gene therapy.
- To explore the influence of vascular support cells and preclinical models in this field.
Main Methods:
- Literature review of anti-angiogenic gene therapy strategies.
- Analysis of different gene delivery vehicles (e.g., viral, non-viral).
- Discussion of preclinical models for evaluating anti-angiogenic cancer gene therapy.
Main Results:
- Gene therapy holds potential for effective anti-angiogenic treatment of solid tumors.
- Various administration vehicles are being explored for targeted delivery.
- Understanding tumor vascular support cells is crucial for optimizing therapy.
- Appropriate preclinical models are essential for successful translation.
Conclusions:
- Anti-angiogenic gene therapy is a rational approach for solid tumor treatment.
- Further research into delivery systems and tumor microenvironment is warranted.
- Selection of suitable preclinical models is critical for advancing the field.